Respiratory Distress Syndrome clinical trials at UC Davis

2 research studies open to eligible people

Showing trials for

  • Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome

    open to eligible people ages 18 years and up

    This is a Phase 2b, randomized, double-blind, placebo-controlled, multi-center study to assess the safety and efficacy of a single dose of Allogeneic Bone Marrow-derived Human Mesenchymal Stromal Cells (hMSCs) infusion in patients with Acute Respiratory Distress Syndrome (ARDS). This study is the extension of the Phase 1 pilot study (NCT01775774) and Phase 2a study (NCT02097641).

    Sacramento 5389489, California 5332921 and other locations

  • I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

    open to eligible people ages 18 years and up

    The goal of this project is to rapidly screen promising agents, in the setting of an adaptive platform trial, for treatment of critically ill COVID-19 patients. In this phase 2 platform design, agents will be identified with a signal suggesting a big impact on reducing mortality and the need for, as well as duration, of mechanical ventilation.

    Davis 5341704, California 5332921 and other locations

Our lead scientists for Respiratory Distress Syndrome research studies include .